PRLD
Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology · US
$5.46
+4.00%Aug 11, 2026, 00:00 UTC
Prelude Therapeutics Inc reported Q2 2026 revenue of $5.704 million, a net loss of $13.921 million, and diluted EPS of -$0.14, with approximately $155 million in cash and marketable securities expected to fund operations into Q2 2028.
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.